A Phase 2, Investigator-Initiated, Feasibility Study to Evaluate the Mechanisms of Coronary Endothelial Dysfunction Imaged As Resting Myocardial Perfusion Heterogeneity After Endothelin Receptor Blockade With Darusentan.

Trial Profile

A Phase 2, Investigator-Initiated, Feasibility Study to Evaluate the Mechanisms of Coronary Endothelial Dysfunction Imaged As Resting Myocardial Perfusion Heterogeneity After Endothelin Receptor Blockade With Darusentan.

Completed
Phase of Trial: Phase II

Latest Information Update: 14 Oct 2014

At a glance

  • Drugs Darusentan (Primary)
  • Indications Coronary artery disease
  • Focus Pharmacodynamics
  • Most Recent Events

    • 06 Oct 2011 Actual end date Aug 2011 added as reported by ClinicalTrials.gov.
    • 06 Oct 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 03 Jan 2011 Planned end date changed from 1 Dec 2009 to 1 Jul 2011as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top